Cancer clinical trials in the region Île-de-France
684 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT07222566
#2025-523461-17-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
4 recruiting sites
Pfizer
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06465953
#2023-510155-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Secondary MDS
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required IPSS-M prognostic scores
Low
Moderately low
Moderately high
High
Very high
Excluded previous treatments
Chemotherapy
Allogeneic stem cell transplant
6 recruiting sites
Servier
Phase 3
Small intestine and appendix cancer
#NCT06878664
#2024-517921-14-00
Required histologic types
Jejunum cancer
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
3 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Head and neck cancer
#NCT06496178
#2023-510322-32-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
14 recruiting sites
Merus
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06641414
#2024-517247-31-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High
Very high
Required IPSS-M prognostic scores
High
Very high
Excluded previous treatments
Allogeneic stem cell transplant
1 recruiting site
Ascentage Pharma Group Inc.
Phase 3
Head and neck cancer
#NCT06129864
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Radiochemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Surgery
Radiotherapy
8 recruiting sites
AstraZeneca
Phase 3
Kidney cancer
#NCT07011719
#2024-515023-11-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
9 recruiting sites
Arcus Biosciences
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
18 recruiting sites
Regeneron Pharmaceuticals
Phase 3
Lymphoma
#NCT06091865
#2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
18 recruiting sites
Regeneron Pharmaceuticals